EzriCare Eye Drops Lawsuit 2026: 81 Infections, 14 Lost Vision, 4 Deaths — and Still No Settlement
EzriCare and Delsam Pharma Artificial Tears were linked by the FDA and CDC in early 2023 to a multistate outbreak of drug-resistant Pseudomonas aeruginosa, leading to a February 2023 recall. As of 2026, there is no MDL consolidation, no certified class action, and no approved settlement — individual lawsuits continue while the litigation slows and most firms stop accepting new cases.
- In May 2023, the CDC reported 81 infections across 18 states linked to the outbreak: 14 patients lost vision, 4 had eyeballs surgically removed, and 4 died.
- The contaminant was a drug-resistant strain of Pseudomonas aeruginosa (VIM-GES-CRPA); 85% of patients who could recall their brand named EzriCare Artificial Tears.
- The products, manufactured by Global Pharma Ltd., were recalled in February 2023, and the FDA has urged consumers never to use the recalled products.
- As of October 2026, no multidistrict litigation has been formed, no class action has been certified, and no settlements or jury trials have occurred.
- A December 2023 refund class-action complaint was filed, and in June 2024 a New Jersey federal judge dismissed Amazon as a defendant in one plaintiff's case.
How Ordinary Eye Drops Became a Public-Health Emergency
Artificial tears are among the most routine products in American medicine cabinets — used for dry eyes, contact-lens comfort, and post-surgical care. The brand most patients reached for in this outbreak was EzriCare Artificial Tears, sold alongside Delsam Pharma's Artificial Tears, both manufactured in India by Global Pharma Ltd. and sold widely, including on Amazon.
On January 31, 2023, the CDC issued an alert recommending that clinicians and patients immediately stop using EzriCare Artificial Tears pending investigation. The agency had identified patients infected with carbapenem-resistant Pseudomonas aeruginosa — CRPA for short, a strain of the common environmental bacterium Pseudomonas aeruginosa that resists carbapenem antibiotics, one of medicine's last-resort classes. Laboratory testing found the same organism in opened bottles of EzriCare Artificial Tears. Of patients who could remember which brand they had used, 85 percent named EzriCare.
In early February 2023, the products were recalled. The FDA's subsequent guidance was unusually blunt: do not use the recalled products under any circumstances, and keep the packaging if you intend to pursue a legal claim.
The Human Cost, in Documented Numbers
The CDC's outbreak reporting tells the story in figures that need no embellishment. By March 2023, the agency had confirmed 68 infections across 16 states, with one death and eight reports of vision loss. By May 2023, the totals had grown: 81 infections in 18 states, 14 patients reporting vision loss, 4 patients who had eyeballs surgically removed, and 4 deaths.
Not every injury was ocular. The same organism caused urinary tract and lung infections in some patients, and the CDC linked at least 38 cases to four healthcare facility clusters. What began as a contaminated consumer product became, in some hospitals, a healthcare-associated outbreak — a fact that shapes how lawyers frame responsibility, reaching beyond the manufacturer toward the entire chain of distribution.
For context on how contaminated-product lawsuits differ from ordinary injury claims — and why they can move either faster or slower — the Problem Solved YouTube channel explains mass-tort mechanics in plain language.
Where the Litigation Stands in 2026
The first lawsuits were filed shortly after the February 2023 recall. Plaintiffs named Global Pharma Healthcare, the U.S. distributors EzriCare LLC and Delsam Pharma, and in some cases the retailers that sold the drops. The allegations follow the classic product-liability script: a sterile product that was not sterile, manufactured under conditions the FDA later cited as unsanitary, distributed for months while infections accumulated.
But the litigation's structure is where the Belviq-like pattern repeats. As of October 2026, the Judicial Panel on Multidistrict Litigation has not consolidated these cases into an MDL, no class action has been certified, and there have been no jury trials or approved settlements. Each case is proceeding individually — which means slower shared discovery, no bellwether verdicts to anchor negotiations, and outcomes that vary case by case.
A few procedural landmarks are worth noting. In December 2023, plaintiff Crystal Roberts filed a class-action complaint seeking a refund of the eye drops' purchase price — a consumer claim distinct from the personal-injury cases, and still uncertified. In January 2024, the New Jersey federal judge handling Roberts v. EzriCare granted plaintiffs leave to file an amended complaint. And in June 2024, that same court dismissed Amazon as a defendant from plaintiff Deborah Hartwell's case, finding she had not shown the New Jersey court had jurisdiction over the retailer — a reminder that who you can sue, and where, is itself a contested question. In mass tort versus class action litigation, that distinction determines everything about how a case proceeds.
The Slowing Clock
Lawyers tracking the litigation describe a case inventory that is slowing down. Most law firms have stopped accepting new EzriCare cases, and some have formally closed their intake. This is not, in itself, a verdict on the cases' merits — firms make intake decisions for business reasons, including the expected cost of litigating individual cases without the efficiencies of an MDL. But it has a practical consequence: finding representation is harder than it was in 2023, and waiting does not improve the odds.
At the same time, attorneys familiar with the claims have told reporters there are potential settlement talks underway — meaning the litigation could wrap up sooner than its slow public pace suggests.
Statutes of limitations remain the hard constraint. The recall was in February 2023; in many states, personal-injury deadlines run two to three years from discovery of the injury. Anyone who suffered an eye infection, vision loss, or a related hospitalization after using these products and has not yet consulted counsel is working against a clock that has already been running for years. Our guide to state-by-state injury claim deadlines maps how narrow the remaining window may be.
Who May Qualify — and What Evidence Matters
People who used recalled EzriCare or Delsam Pharma Artificial Tears and developed a serious eye infection, vision loss, or a related hospitalization — or families of those who died — may qualify for a claim, depending on the diagnosis, the product used, and the facts of each case.
The strongest evidence is contemporaneous: the recalled bottle or its packaging (the FDA explicitly advised keeping it), pharmacy or purchase records — Amazon order histories have been cited in filings — medical records documenting the infection and its treatment, and CDC or hospital confirmation that the infecting organism was the outbreak strain.
What to Do Right Now
First, if you still have the recalled product in your home, stop using it and do not throw it away — packaging is evidence. Second, have an attorney experienced in product-liability litigation evaluate your timeline immediately; the combination of expiring deadlines and a shrinking plaintiff bar means delay carries a double cost.
Third, keep expectations honest. There is no settlement fund, no published payment schedule, and no guaranteed recovery — and anyone quoting one is selling something. Compensation in these cases depends entirely on individual circumstances: the severity of the injury, its economic consequences, and the strength of the evidence linking product to harm. Most settlements in pharmaceutical and product cases are confidential, and the documented facts — 81 infections, 14 blinded, 4 dead — speak more powerfully than any projected figure.
This article provides general information only and is not legal or medical advice. EzriCare litigation involves state-specific deadlines and individual facts; consult a qualified attorney about your situation and a medical professional about your health.
Who Benefits From This — and Who Does Not
Who benefits most from this guide:
People who used recalled EzriCare or Delsam Pharma Artificial Tears and developed a serious eye infection, vision loss, or related hospitalization, or families of those who died. How: the CDC reported 81 infections across 18 states by May 2023, with 14 patients losing vision, 4 having eyeballs surgically removed, and 4 deaths, and eligibility depends on the diagnosis, the product used, and each case's facts.
People who kept the product and its packaging. How: the FDA urged consumers never to use the recalled products, and its guidance was to keep the packaging if you intend to pursue a legal claim.
Patients whose linked infection was not only in the eyes. How: the same organism caused urinary tract and lung infections in some patients, and the CDC linked at least 38 cases to four healthcare facility clusters, so the injury pattern reaches beyond eye drops used at home.
Who does not benefit:
Anyone expecting a settlement or class payout now. How: as of October 2026 no multidistrict litigation has been formed, no class action has been certified, and no settlements or jury trials have occurred, and the December 2023 complaint sought only a refund of the purchase price and is still uncertified.
Anyone who used the product with no injury and no loss. How: these cases are built on an injury tied to a contaminated product that was not sterile, not on buying a recalled bottle alone.
Anyone assuming retailer liability is automatic. How: retailer responsibility is case-specific, and in June 2024 a New Jersey federal judge dismissed Amazon as a defendant in one plaintiff's case, so each defendant's role has to be argued on its own facts.
Because these cases proceed individually rather than through an MDL or a class action, our guide to mass-tort vs. class action explains how the two structures differ.
Is there an EzriCare class action lawsuit?
No certified class action exists as of 2026. A December 2023 complaint sought refunds for purchasers, but no class has been certified, and personal-injury cases are proceeding as individual lawsuits rather than through a multidistrict litigation.
Has there been an EzriCare settlement?
No. As of October 2026, there have been no approved settlements and no jury trials in the EzriCare litigation. Lawyers familiar with the claims have reported potential settlement talks, but nothing official has been announced.
Who can file an EzriCare lawsuit?
People who used recalled EzriCare or Delsam Pharma Artificial Tears and developed a serious eye infection, vision loss, or related hospitalization — or families of those who died — may qualify. Eligibility depends on the diagnosis, the product used, and each case's facts, and statutes of limitations apply.
What caused the EzriCare infections?
The CDC and FDA linked the products to a drug-resistant strain of Pseudomonas aeruginosa (VIM-GES-CRPA). The same organism was found in opened bottles of EzriCare Artificial Tears, and 85% of patients who could recall their brand named EzriCare.
Who benefits most from an EzriCare lawsuit?
People who used recalled EzriCare or Delsam Pharma Artificial Tears and developed a serious eye infection, vision loss, or related hospitalization benefit most, as do families of those who died, because eligibility depends on the diagnosis, the product used, and each case's facts, with the CDC totals of 81 infections, 14 patients losing vision, and 4 deaths showing the documented scale of the outbreak.
How do I start an EzriCare claim?
Keep the product packaging and any purchase records, gather the diagnosis and treatment records for the infection or vision loss, note the brand used and the February 2023 recall, and speak with a product-liability attorney promptly, since statutes of limitations apply and each case proceeds individually rather than through a multidistrict litigation.